REFERENCES
1. IQVIA® National Prescription Audit® - TRx/EUTRx Data: November 2022 – February 2023 (claim derived from the use of information under license from IQVIA, which expressly reserves all
rights, including rights of copying, distribution, and republication). 2. IQVIA® Patients Insights New To Brand (NBRx) Data: since launch – January 2023 (claim derived from the use of
information under license from IQVIA, which expressly reserves all rights, including rights of copying, distribution, and republication). 3. Lo Loestrin® Fe prescribing information. Madison, NJ:
Allergan USA, Inc. 4. U.S. Food and Drug Administration. The Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Available from: https://
www.accessdata.fda.gov/scripts/cder/ob/. Accessed July 2022. 5. Data on file. Allergan USA, Inc.: Madison, NJ. 6. Managed Markets Insight and Technology, LLC™, a trademark of MMIT.
Database as of March 2022. Data are subject to change. 7. Junel® Fe 1/20 prescribing information. North Wales, PA: Teva Pharmaceuticals USA; 2017. 8. The Alan Guttmacher Institute.
Next Steps for America’s Family Planning Program: Leveraging the Potential of Medicaid and Title X in an Evolving Health Care System. https://www.guttmacher.org/sites/default/files/
report_pdf/nextsteps.pdf. Accessed July 2022. 9. Previfem® prescribing information. Huntsville, AL: Qualitest Pharmaceuticals; 2015. 10. Microgestin® Fe 1.5/30 prescribing information.
Greenville, NC: Mayne Pharma; 2020. 11. Ortho Tri-Cyclen® Lo prescribing information. Titusville, NJ: Janssen Pharmaceuticals, Inc; 2019. 12. Nakajima ST, Archer DF, Ellman H.
Contraception. 2007;75(1):16-22. 13. Willis SA, Kuehl TJ, Spiekerman AM, Sulak PJ. Contraception. 2006;74(2):100-103. 14. Spona J, Elstein M, Feichtinger W, et al. Contraception.
1996;54(2):71-77. 15. Archer OF, Nakajima ST, Sawyer AT, et al. Obstet Gynecol. 2013;122(3):601-607.